Table 3.
Summary of the epidemiologic literature on PFAS exposures and immunotoxicity.a
| Outcome | # of total studies | # of significant studies |
# of significant studies by each PFAS |
|---|---|---|---|
| Vaccine antibody | 5 | 4 | Mixture: 1; PFOA: 2; PFNA: 1; PFHxS: 1; PFOS: 2 |
| Immune markers | 7 | 5 | PFHpA: 1; PFOA: 5; PFNA: 2; PFDA: 1; PFTeDA: 1; PFDoA: 1; PFBS: 1; PFHxS: 2; PFOS: 4 |
| Asthma and biomarker of asthma | 9 | 5 | PFHpA: 1; PFOA: 5; PFNA: 3; PFDA: 3; PFDoDA: 1; PFBS: 1; PFHxS: 2; PFOS: 4 |
| Infection and other autoimmune diseases | 13 | 8 | PFOA: 6; PFOS: 4; PFDA: 1; PFDoDA: 1; PFNA: 2; PFUnDA: 1; PFHxS: 2; PFOSA: 1 |
| Allergy | 6 | 1 | PFOA: 1; PFHxS: 1; PFOS: 1 |
a
Details of the studies examined are provided in the Supporting Information Table S2.